Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

NCT04210492 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT04210492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04210492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Lead sponsor
Yale University
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 26, 2020
Completion date
January 31, 2030
Enrollment
36 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer